Materias dentro de su búsqueda.
Mostrando 1,001 - 1,020 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.28s Limitar resultados
  1. 1001
    “…Recent clinical trials suggest an emerging role for HER2-targeted therapy. Testing for HER2 expression in UC is not part of current routine clinical practice. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 expression in urothelial carcinoma, a systematic literature review
  2. 1002
    “…The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Targeting HER2-positive breast cancer: advances and future directions
  3. 1003
    “…One in eight women will be diagnosed with breast cancer in their lifetime and approximately 25% of those cases will be HER2-positive. Current methods for diagnosing HER2-positive breast cancer involve using IHC and FISH from suspected cancer biopsies to quantify HER2 expression. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of (68)Ga-Radiolabeled Peptides for HER2 PET Imaging
  4. 1004
    “…Most women with HER2-positive breast cancer receive neoadjuvant chemotherapy plus HER2-targeted therapies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
  5. 1005
    “…Pyrotinib is safe and effective for elderly patients with advanced HER2 positive BC.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
  6. 1006
    por Cobain, Erin F., Hayes, Daniel F.
    Publicado 2022
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm
  7. 1007
    “…Loss of HER2 in previously HER2-positive breast tumors is not rare, occurring in up to 50% of breast cancers; however, clinical research and practice underestimate this issue. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
  8. 1008
    por Eli, Lisa D., Kavuri, Shyam M.
    Publicado 2022
    “…Human epidermal growth factor receptor 2 (HER2) is a major drug target and clinical biomarker in breast cancer treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
  9. 1009
    “…BACKGROUND: Emerging evidence indicates that breast cancer (BC) patients whose tumours express HER2 protein without HER2 gene amplification (HER2‐low), can benefit from antibody–drug conjugates (ADC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Refining the definition of HER2‐low class in invasive breast cancer
  10. 1010
    “…In patients with metastatic HER2+ breast cancer (BC), the combination of trastuzumab and vinorelbine (TV) is effective and well tolerated. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
  11. 1011
    “…To examine the prognostic value of claudin 18.2 (CLDN18.2) and human epidermal growth factor receptor-2 (HER-2) expression in patients with resected pancreatic ductal adenocarcinoma (PDAC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
  12. 1012
    “…PURPOSE: The development of human epidermal growth factor receptor 2 (HER2)-directed therapies has revolutionized the treatment of HER2-positive breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Review of the status of neoadjuvant therapy in HER2-positive breast cancer
  13. 1013
    por Collins, Kenneth
    Publicado 2021
    “…Dr Hetty Ockrim was a general practitioner in an inner-city Glasgow district for 43 years, before retiring in 1989. This paper looks at her career and her legacy through the pioneering oral history study she undertook, on retirement, with former patients, and the ‘Letters to No-one’ written at the time of her retirement but only discovered at the time of her death.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dr Hetty Brenda Ockrim (1919–2007) and her medical legacy
  14. 1014
    “…The HER2(+) subtype of human breast cancer is associated with the malignant transformation of luminal ductal cells of the mammary epithelium. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-driven breast cancer suppression by the JNK signaling pathway
  15. 1015
    “…Around 20% of breast cancers are associated with amplification or overexpression of human epidermal growth factor receptor 2 (HER2). In this setting, anti-HER2-targeted agents are the cornerstone of cancer therapeutic strategies. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks
  16. 1016
    “…HER2-low is currently defined as a HER2 immunohistochemical expression of 1+ or 2+ without amplification by in-situ hybridization. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    How I treat HER2-low advanced breast cancer
  17. 1017
    “…We have evaluated the clinicopathologic characteristics and genomic profiles of real-world hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (MBC) patients to examine the determinants of outcome for younger vs. older patients in a single clinical subtype undergoing treatment in the same clinic. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
  18. 1018
    “…BACKGROUND: Despite major improvements in treatment of HER2-positive metastatic breast cancer (MBC), only few patients achieve complete remission and remain progression free for a prolonged time. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
  19. 1019
    “…Discrepancies have been reported between HER2 status in primary breast cancer and micrometastatic cells in bone marrow. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
  20. 1020
    “…INTRODUCTION: Inhibiting the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of breast carcinoma cells, and this is linked to human epidermal growth factor receptor 2 (HER2) signaling pathways in models of simultaneous expression of FASN and HER2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
Herramientas de búsqueda: RSS